Karyopharm Therapeutics (KPTI) Long-Term Investments (2014 - 2021)

Karyopharm Therapeutics has reported Long-Term Investments for 8 years, with the latest figure at $2.0 million in Q3 2021.

• For the quarter ending Q3 2021, Long-Term Investments fell 94.91% year-over-year to $2.0 million; the trailing twelve-month figure through Sep 2021 stood at $2.0 million (down 94.91% YoY), and the FY2020 full-year result was $24.2 million, up 1101.14% from the prior year.
• Long-Term Investments for Q3 2021 stood at $2.0 million, roughly flat from $2.0 million in the prior quarter.
• The five-year high for Long-Term Investments was $48.9 million in Q2 2020, with the low at $2.0 million in Q4 2018.
• Historically, Long-Term Investments has averaged $19.5 million across 5 years, with a median of $10.3 million in 2018.
• Annual changes were most pronounced in 2020 — Long-Term Investments soared 1847.13% — and 2021, when it tumbled 95.89%.
• Karyopharm Therapeutics' Long-Term Investments stood at $29.4 million in 2017, then sank by 93.19% to $2.0 million in 2018, then advanced by 0.75% to $2.0 million in 2019, then soared by 1101.14% to $24.2 million in 2020, then slumped by 91.72% to $2.0 million in 2021.
• The last three Long-Term Investments figures came in at $2.0 million (Q3 2021), $2.0 million (Q2 2021), and $7.7 million (Q1 2021), per Business Quant data.